FDA expert panel to review Merck's new HIV treatment Isentress in September.
D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000494:pharmacology*; D017277:Drug Approval; D015658:HIV Infections / Q000188:drug therapy*; D009930:Organic Chemicals / Q000009:adverse effects* / Q000494:pharmacology*; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium
D019380:Anti-HIV Agents; D009930:Organic Chemicals; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium